Details

Autor(en) / Beteiligte

• Spragg, Roger G
• Lewis, James F
• Walmrath, Hans-Dieter
• Johannigman, Jay
• Bellingan, Geoff
• Laterre, Pierre-Francois
• Witte, Michael C
• Richards, Guy A
• Rippin, Gerd
• Rathgeb, Frank
• Häfner, Dietrich
• Taut, Friedemann J.H
• Seeger, Werner

Titel

Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome

Ist Teil von

• The New England journal of medicine, 2004-08, Vol.351 (9), p.884-892

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The acute respiratory distress syndrome (ARDS) results from a deficiency of functional surfactant in the airways. These investigators carried out a multicenter study in which patients with ARDS were treated with a recombinant human surfactant protein C–based surfactant. No clinical benefits were noted. A multicenter study in which patients with ARDS were treated with a recombinant human surfactant protein C–based surfactant. Although exogenous surfactant is of proven benefit in the prevention and treatment of the respiratory distress syndrome in infants, 1 its value in treating patients with the acute respiratory distress syndrome (ARDS) has not been established. Whereas infants with an immature lung have a deficit in surfactant production, patients with ARDS have decreased surfactant production as well as biochemical alterations of endogenous surfactant that impair surface-tension–lowering properties and decreased surfactant function in distal airways. 2 Normally, pulmonary surfactant phospholipids, acting in concert with surfactant proteins A, B, and C, cause alveolar surface tension to reach very low values at end expiration, thus . . .